tiprankstipranks
Advertisement
Advertisement
Barinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
PremiumCompany AnnouncementsBarinthus’ VTP-300 Hepatitis B Study Reaches Completion: What Investors Should Watch Next
4M ago
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
Premium
Company Announcements
Barinthus Biotherapeutics appoints Douglas Swirsky as CFO
4M ago
Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change
Premium
Company Announcements
Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change
5M ago
Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
PremiumRatingsPromising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics
9M ago
Barinthus Biotherapeutics Updates on AVALON Trial Progress
Premium
Company Announcements
Barinthus Biotherapeutics Updates on AVALON Trial Progress
9M ago
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
Premium
The Fly
Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000
9M ago
Barinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial
PremiumCompany AnnouncementsBarinthus Biotherapeutics Advances Celiac Disease Treatment with VTP-1000 Trial
10M ago
Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
Premium
Company Announcements
Barinthus Biotherapeutics Announces Merger with Clywedog Therapeutics
11M ago
Barinthus Bio, Clywedog enter definitive merger agreement
Premium
The Fly
Barinthus Bio, Clywedog enter definitive merger agreement
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100